Nepafenac
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Nepafenac: From Post-Cataract Surgery Ocular Inflammation to Broader Eye Disease
One-Sentence Summary
The drug-level mechanism of action field for Nepafenac is a recorded data gap, but the clinical trial evidence pack consistently identifies it as a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID), already used and studied for inflammation and pain control following cataract surgery. The TxGNN model predicts it may be effective more broadly for Eye Disease, with 40 clinical trials currently supporting this direction, though no literature (PubMed) evidence has yet been indexed for this specific prediction. Note: the product is currently not marketed in this jurisdiction and a blocking safety data gap (missing SmPC warnings/contraindications) means the candidate cannot yet pass initial safety screening.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the evidence pack’s regulatory fields (data gap). Trial evidence (comparator products Nevanac™/Ilevro™, both marketed nepafenac ophthalmic suspensions) indicates established use for prevention/treatment of ocular inflammation and pain associated with cataract surgery |
| Predicted New Indication | Eye disease (general) |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L1 (≥10 completed Phase 3 RCTs identified) |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Nepafenac is not available in the evidence pack (data gap DG002). However, the clinical trial evidence itself consistently describes Nepafenac as a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) — for example, multiple trials directly compare it against other topical NSAIDs (diclofenac, ketorolac, bromfenac) for control of ocular inflammation, and describe its role in inhibiting prostaglandin-mediated (COX pathway) inflammatory processes in the eye (e.g. NCT03597867, which measured vitreous PGE2 levels after nepafenac administration).
The predicted new indication, “Eye Disease,” is a broad category rather than a single novel condition. Given that the overwhelming majority of supporting trials already relate to established ocular inflammatory conditions — post-cataract surgery inflammation and pain, diabetic macular oedema, post-vitrectomy/retinal detachment inflammation, and post-intravitreal injection discomfort — this prediction largely reflects reinforcement of Nepafenac’s known pharmacological class action (topical anti-inflammatory) rather than an entirely mechanistically novel repurposing signal.
Mechanistically, this is plausible: ocular inflammatory conditions across different anatomical sub-sites (anterior segment post-surgical inflammation, posterior segment macular oedema, vitreoretinal inflammation) share overlapping prostaglandin-driven inflammatory pathways, which a topical COX-inhibiting NSAID could plausibly address. This is consistent with the trial evidence pack, which shows active investigation of Nepafenac across several distinct ocular inflammatory presentations beyond the primary cataract-surgery indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01109173 | Phase 3 | Completed | 2,120 | Pivotal safety/efficacy trial of Nepafenac 0.3% for prevention and treatment of post-cataract surgery ocular inflammation and pain |
| NCT01853072 | Phase 3 | Completed | 881 | Nepafenac 0.3% once-daily superior to vehicle for clinical outcomes among diabetic subjects following cataract surgery |
| NCT01872611 | Phase 3 | Completed | 819 | Companion trial confirming superiority of Nepafenac 0.3% vs vehicle in diabetic post-cataract surgery patients |
| NCT01318499 | Phase 2 | Completed | 1,342 | Dose-ranging comparison of Nepafenac 0.3% vs 0.1% vs vehicle for post-cataract inflammation and pain |
| NCT03499873 | Phase 3 | Completed | 448 | Bioequivalence study of generic Nepafenac 0.3% vs Ilevro™ for post-cataract pain and inflammation |
| NCT01426854 | Phase 3 | Completed | 260 | Nepafenac 0.1% superior to vehicle for ocular inflammation/pain in Chinese cataract surgery subjects |
| NCT00333255 | Phase 3 | Completed | 267 | Nepafenac 0.1% vs Acular LS for pre/post-operative cataract surgery inflammation |
| NCT00405730 | Phase 3 | Completed | 227 | European study: Nepafenac 0.1% vs ketorolac vs placebo for post-cataract inflammation and pain |
| NCT00332774 | Phase 3 | Completed | 149 | 3-month safety comparison of Nepafenac 0.1% vs Acular LS and vehicle post-cataract surgery |
| NCT00780780 | Phase 3 | Completed | 40 | Nepafenac plus triamcinolone vs intravitreal triamcinolone for clinically significant diabetic macular oedema |
40 clinical trials in total were identified; the 10 most relevant/largest are shown above.
Literature Evidence
Currently no related literature is available for this specific predicted indication (Eye Disease). Related preclinical literature exists for adjacent indications (e.g. optic papillitis, PMID 14635785) but was not indexed against this specific prediction.
UK Market Information
No marketing authorisations were found for Nepafenac in the evidence pack. The product is currently recorded as Not Marketed (0 licenses on file).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Important note: A blocking data gap has been recorded (DG001 — TFDA/SmPC-equivalent warnings and contraindications not yet obtained). This prevents completion of an initial safety assessment (S1 stage) for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: Although the predicted indication (Eye Disease) is well supported by a large body of completed Phase 3 clinical trial evidence (L1), largely reflecting Nepafenac’s established pharmacology as a topical ocular NSAID, two blocking issues prevent progression: (1) the drug currently holds no UK marketing authorisation, and (2) core safety data (warnings, contraindications) is a recorded blocking gap, meaning initial safety screening cannot be completed.
To proceed, the following is needed:
- SmPC-equivalent warnings and contraindications (DG001, Blocking) — required before any S1 safety assessment
- Confirmed mechanism of action documentation (DG002, High) from DrugBank or equivalent source
- Clarification of UK regulatory pathway, given current “Not Marketed” status and zero licenses
- PubMed literature search specific to the “Eye Disease” prediction, as none is currently indexed
- Clarification of what “Eye Disease” specifically denotes as a target indication, given its breadth relative to the existing cataract-surgery evidence base
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.